目的快速制备并分离纯化硫化氢特异性荧光探针(Washington State Probe-5),建立动物组织中硫化氢的荧光探针测定法,并在癌性胸水模型中进行方法适用性验证。方法优化条件分离纯化WSP-5;对荧光探针反应液配制溶剂、DMSO加入体积、pH、反...目的快速制备并分离纯化硫化氢特异性荧光探针(Washington State Probe-5),建立动物组织中硫化氢的荧光探针测定法,并在癌性胸水模型中进行方法适用性验证。方法优化条件分离纯化WSP-5;对荧光探针反应液配制溶剂、DMSO加入体积、pH、反应液溶剂和反应液体积、样品前处理温度、研磨次数、研磨后静置时间等条件进行考察;以S-180腹水瘤细胞建立癌性胸水小鼠模型,测定小鼠各脏器中的硫化氢含量。结果以硅胶和葡聚糖凝胶为固定相,二氯甲烷-甲醇-甲酸(60∶1∶0.1,V/V/V)和二氯甲烷-甲醇(1∶1,V/V)为洗脱剂制备WSP-5纯品;动物组织样本和硫氢化钠标准溶液加入优化后的5倍量冰冷反应液,低温研磨、高速离心,上清液避光孵育12 h,测定荧光强度并计算硫化氢浓度;该方法检测限约0.6μmol·L^(-1),定量限1μmol·L^(-1),在硫氢化钠一定浓度范围内,浓度与荧光强度线性系数均大于0.99;在癌性胸水小鼠模型中,各脏器硫化氢含量随着注射癌细胞数量的增多均有不同程度的增加趋势。结论该方法操作简单、成本低、灵敏度高、特异性强,适合各类组织样本的高通量检测,可为硫化氢相关药效机制的深入研究和相关药物开发提供方法学参考。展开更多
Objective: To evaluate the efficacy and safety of Tibetan medicine Ruyi Zhenbao Pills(RZPs) in the treatment of patients with motor and sensory dysfunction after stroke. Methods: A total of 120 convalescent stroke pat...Objective: To evaluate the efficacy and safety of Tibetan medicine Ruyi Zhenbao Pills(RZPs) in the treatment of patients with motor and sensory dysfunction after stroke. Methods: A total of 120 convalescent stroke patients hospitalized in the Rehabilitation Department of Guangdong Provincial Hospital of Chinese Medicine from June 2017 to December 2019 were enrolled in this trial. Patients were assigned to control(60 cases) and research(60 cases) groups by computer random assignment. All patients received internal treatment and modern rehabilitation training. On this basis, the research group was given oral RZPs for 4 weeks, while the control group was given oral placebo. The primary outcome was motor function of the affected side evaluated by simplified FuglMeyer Motion Assessment Scale(FMA-M). The secondary outcomes included sensory function, activity of daily living(ADL), quality of life, balance function, and pain, which were assessed by Fugl-Meyer Sensory Assessment Scale(FMA-S), Modified Barthel Index(MBI), Special Scale of the Quality of Life(SS-QOL), Berg Balance Scale(BBS), and Visual Analogue Scale(VAS), respectively. All of the assessments were performed before treatment, and 4 and 8 weeks after treatment. Vital signs, liver and kidney functions, routine blood test, blood coagulation profile, and routine urinalysis of patients were monitored. Results: After 4-week treatment, the FMA-M, BBS and FMA-S scores in the research group significantly increased compared with the control group(P<0.05). At 8-week follow-up, the BBS and MBI scores in the research group were higher than the control group(P<0.05). There was no statistical difference between the 2 groups in the SS-QOL and VAS scores at 4 and 8 weeks(P>0.05). Moreover, after treatment, there was no significant difference in vital signs, liver and kidney functions, blood coagulation function, blood routine and urinalysis between the 2 groups(P>0.05). Conclusion: RZPs improved limb motor, balance, and sensory functions of stroke patients during recovery period with good safety.(Trial registration No. NCT04029701)展开更多
文摘目的快速制备并分离纯化硫化氢特异性荧光探针(Washington State Probe-5),建立动物组织中硫化氢的荧光探针测定法,并在癌性胸水模型中进行方法适用性验证。方法优化条件分离纯化WSP-5;对荧光探针反应液配制溶剂、DMSO加入体积、pH、反应液溶剂和反应液体积、样品前处理温度、研磨次数、研磨后静置时间等条件进行考察;以S-180腹水瘤细胞建立癌性胸水小鼠模型,测定小鼠各脏器中的硫化氢含量。结果以硅胶和葡聚糖凝胶为固定相,二氯甲烷-甲醇-甲酸(60∶1∶0.1,V/V/V)和二氯甲烷-甲醇(1∶1,V/V)为洗脱剂制备WSP-5纯品;动物组织样本和硫氢化钠标准溶液加入优化后的5倍量冰冷反应液,低温研磨、高速离心,上清液避光孵育12 h,测定荧光强度并计算硫化氢浓度;该方法检测限约0.6μmol·L^(-1),定量限1μmol·L^(-1),在硫氢化钠一定浓度范围内,浓度与荧光强度线性系数均大于0.99;在癌性胸水小鼠模型中,各脏器硫化氢含量随着注射癌细胞数量的增多均有不同程度的增加趋势。结论该方法操作简单、成本低、灵敏度高、特异性强,适合各类组织样本的高通量检测,可为硫化氢相关药效机制的深入研究和相关药物开发提供方法学参考。
基金Supported by SHEN Bao-fan Academic Experience Inheritance Studio of Guangdong Provincial Hospital of Chinese Medicine。
文摘Objective: To evaluate the efficacy and safety of Tibetan medicine Ruyi Zhenbao Pills(RZPs) in the treatment of patients with motor and sensory dysfunction after stroke. Methods: A total of 120 convalescent stroke patients hospitalized in the Rehabilitation Department of Guangdong Provincial Hospital of Chinese Medicine from June 2017 to December 2019 were enrolled in this trial. Patients were assigned to control(60 cases) and research(60 cases) groups by computer random assignment. All patients received internal treatment and modern rehabilitation training. On this basis, the research group was given oral RZPs for 4 weeks, while the control group was given oral placebo. The primary outcome was motor function of the affected side evaluated by simplified FuglMeyer Motion Assessment Scale(FMA-M). The secondary outcomes included sensory function, activity of daily living(ADL), quality of life, balance function, and pain, which were assessed by Fugl-Meyer Sensory Assessment Scale(FMA-S), Modified Barthel Index(MBI), Special Scale of the Quality of Life(SS-QOL), Berg Balance Scale(BBS), and Visual Analogue Scale(VAS), respectively. All of the assessments were performed before treatment, and 4 and 8 weeks after treatment. Vital signs, liver and kidney functions, routine blood test, blood coagulation profile, and routine urinalysis of patients were monitored. Results: After 4-week treatment, the FMA-M, BBS and FMA-S scores in the research group significantly increased compared with the control group(P<0.05). At 8-week follow-up, the BBS and MBI scores in the research group were higher than the control group(P<0.05). There was no statistical difference between the 2 groups in the SS-QOL and VAS scores at 4 and 8 weeks(P>0.05). Moreover, after treatment, there was no significant difference in vital signs, liver and kidney functions, blood coagulation function, blood routine and urinalysis between the 2 groups(P>0.05). Conclusion: RZPs improved limb motor, balance, and sensory functions of stroke patients during recovery period with good safety.(Trial registration No. NCT04029701)
